Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 6 (2009), Issue 10 (October)

1. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases.
   Nat Rev Drug Discov, 8(10): 794-805. [Abstract] [Full-text]
2. Treatment of choroidal neovascularization associated with Best's disease in children.
   J Pediatr Ophthalmol Strabismus, 46(5): 306-11. [Abstract] [Full-text]
3. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004).
   Lancet Oncol, 10(10): 957-66. [Abstract] [Full-text]
4. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.
   J Clin Oncol, 27(27): 4548-54. [Abstract] [Full-text]
5. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.
   J Clin Oncol, 27(27): 4578-84. [Abstract] [Full-text]
6. Use of hormone replacement therapy and the risk of colorectal cancer.
   J Clin Oncol, 27(27): 4542-7. [Abstract] [Full-text]
7. Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck.
   J Clin Oncol, 27(27): 4448-53. [Abstract] [Full-text]
8. Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402.
   J Clin Oncol, 27(27): 4487-91. [Abstract] [Full-text]
9. Targeting VEGF-encapsulated immunoliposomes to MI heart improves vascularity and cardiac function.
   FASEB J, 23(10): 3361-7. [Abstract] [Full-text]
10. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab.
    Neuro Oncol, 11(5): 550-5. [Abstract] [Full-text]
11. Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.
    Neuro Oncol, 11(5): 556-61. [Abstract] [Full-text]
12. Antiangiogenic approaches to age-related macular degeneration today.
    Ophthalmology, 116(10): S15-23. [Abstract] [Full-text]
13. Erythropoietin to augment myocardial salvage induced by coronary thrombolysis in patients with ST segment elevation acute myocardial infarction.
    Am J Cardiol, 104(8): 1035-40. [Abstract] [Full-text]
14. Complications associated with postoperative antibiotic prophylaxis after breast surgery.
    Am J Surg, 198(4): 553-6. [Abstract] [Full-text]
15. Complement factor H Y402H and C-reactive protein polymorphism and photodynamic therapy response in age-related macular degeneration.
    Ophthalmology, 116(10): 1908-12.e1. [Abstract] [Full-text]
16. Photochemical internalization of bleomycin before external-beam radiotherapy improves locoregional control in a human sarcoma model.
    Int J Radiat Oncol Biol Phys, 75(3): 878-85. [Abstract] [Full-text]
17. Cost-effectiveness analysis of intracameral cefuroxime use for prophylaxis of endophthalmitis after cataract surgery.
    Ophthalmology, 116(10): 1887-96.e1. [Abstract] [Full-text]
18. Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer.
    Int J Cancer, 125(11): 2721-7. [Abstract] [Full-text]
19. Radiochemotherapy including cisplatin alone versus cisplatin + 5-fluorouracil for locally advanced unresectable stage IV squamous cell carcinoma of the head and neck.
    Strahlenther Onkol, 185(10): 675-81. [Abstract] [Full-text]
20. Oral rehydration solutions in non-cholera diarrhea: a review.
    Am J Gastroenterol, 104(10): 2596-604; quiz 2605. [Abstract] [Full-text]
21. Postsynthetic modifications of iron-carboxylate nanoscale metal-organic frameworks for imaging and drug delivery.
    J Am Chem Soc, 131(40): 14261-3. [Abstract] [Full-text]
22. Quality of medication use in primary care--mapping the problem, working to a solution: a systematic review of the literature.
    BMC Med, 7: 50. [Abstract] [Full-text]
23. Enzyme-triggered disassembly of dendrimer-based amphiphilic nanocontainers.
    J Am Chem Soc, 131(40): 14184-5. [Abstract] [Full-text]
24. Targeted therapy to the IL-2R using diphtheria toxin and caspase-3 fusion proteins modulates Treg and ameliorates inflammatory colitis.
    Eur J Immunol, 39(10): 2850-64. [Abstract] [Full-text]
25. Strategies for optimizing targeting and delivery of mucosal HIV vaccines.
    Eur J Immunol, 39(10): 2657-69. [Abstract] [Full-text]
26. Nanowired-drug delivery enhances neuroprotective efficacy of compounds and reduces spinal cord edema formation and improves functional outcome following spinal cord injury in the rat.
    Acta Neurochir Suppl, 106: 343-50. [Abstract] [Full-text]
27. Selected combination of neurotrophins potentiate neuroprotection and functional recovery following spinal cord injury in the rat.
    Acta Neurochir Suppl, 106: 295-300. [Abstract] [Full-text]
28. Procedure-oriented sectional anatomy of the shoulder.
    J Comput Assist Tomogr, 33(5): 814-7. [Abstract] [Full-text]
29. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial.
    Lancet, 374(9697): 1243-51. [Abstract] [Full-text]
30. Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy.
    Biochem Pharmacol, 78(11): 1366-73. [Abstract] [Full-text]
31. The reliable targeting of specific drug release profiles by integrating arrays of different albumin-encapsulated microsphere types.
    Biomaterials, 30(34): 6648-54. [Abstract] [Full-text]
32. Intraoperative and postoperative effects of corneal collagen cross-linking on progressive keratoconus.
    Arch Ophthalmol, 127(10): 1258-65. [Abstract] [Full-text]
33. New-onset breast tenderness after initiation of estrogen plus progestin therapy and breast cancer risk.
    Arch Intern Med, 169(18): 1684-91. [Abstract] [Full-text]
34. The HAART cell phone adherence trial (WelTel Kenya1): a randomized controlled trial protocol.
    Trials, 10: 87. [Abstract] [Full-text]
35. Intranasal delivery of ESBA105, a TNF-alpha-inhibitory scFv antibody fragment to the brain.
    J Neuroimmunol, 215(1): 65-72. [Abstract] [Full-text]
36. BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide.
    Gynecol Oncol, 115(2): 193-8. [Abstract] [Full-text]
37. The effect of hospital operative volume, residual tumor and first-line chemotherapy on survival of ovarian cancer - a prospective nation-wide study in Finland.
    Gynecol Oncol, 115(2): 199-203. [Abstract] [Full-text]
38. Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study).
    Br J Cancer, 101(8): 1261-8. [Abstract] [Full-text]
39. Gene expression profile and response to trastuzumab-docetaxel-based treatment in breast carcinoma.
    Br J Cancer, 101(8): 1357-64. [Abstract] [Full-text]
40. Non-transferrin-bound iron in haematological patients during chemotherapy and conditioning for autologous stem cell transplantation.
    Eur J Haematol, 83(5): 455-9. [Abstract] [Full-text]
41. Bortezomib plus dexamethasone is highly effective in relapsed and refractory myeloma patients but responses are short-lived.
    Eur J Haematol, 83(5): 449-54. [Abstract] [Full-text]
42. Protodynamic therapy for bladder cancer: in vitro results of a novel treatment concept.
    BJU Int, 104(9): 1233-8. [Abstract] [Full-text]
43. Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study.
    Leukemia, 23(10): 1763-70. [Abstract] [Full-text]
44. Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia.
    Leukemia, 23(10): 1771-8. [Abstract] [Full-text]
45. Assessing the clinical or pharmaco-economical benefit of target controlled desflurane delivery in surgical patients using the Zeus anaesthesia machine.
    Anaesthesia, 64(11): 1229-35. [Abstract] [Full-text]
46. The economics of treating stroke as an acute brain attack.
    BMC Med, 7: 51. [Abstract] [Full-text]
47. Comparing progression of non-functioning pituitary adenomas in hypopituitarism patients with and without long-term GH replacement therapy.
    Eur J Endocrinol, 161(5): 663-9. [Abstract] [Full-text]
48. Hypothalamic involvement predicts cardiovascular risk in adults with childhood onset craniopharyngioma on long-term GH therapy.
    Eur J Endocrinol, 161(5): 671-9. [Abstract] [Full-text]
49. Craniofacial venous malformations: magnetic resonance imaging features that predict treatment outcome.
    J Oral Maxillofac Surg, 67(11): 2388-96. [Abstract] [Full-text]
50. Intravascular large B-cell lymphoma: remission after rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy.
    J Am Acad Dermatol, 61(5): 885-8. [Abstract] [Full-text]
51. Serum retinol-binding protein 4 correlates with obesity, insulin resistance, and dyslipidemia in HIV-infected subjects receiving highly active antiretroviral therapy.
    Metabolism, 58(11): 1523-9. [Abstract] [Full-text]
52. Family caregiver skills in medication management for hospice patients: a qualitative study to define a construct.
    J Gerontol B Psychol Sci Soc Sci, 64(6): 799-807. [Abstract] [Full-text]
53. Increased vulnerability of the spinal cord to radiation or intrathecal chemotherapy during adolescence: A report from the Children's Oncology Group.
    Pediatr Blood Cancer, 53(7): 1205-10. [Abstract] [Full-text]
54. Neuroblastoma involvement of the falx cerebri.
    Pediatr Blood Cancer, 53(7): 1337-9. [Abstract] [Full-text]
55. Autologous stem cell transplant in a patient with Down syndrome and relapsed Hodgkin lymphoma.
    Pediatr Blood Cancer, 53(7): 1327-8. [Abstract] [Full-text]
56. A focal lesion in the falx cerebri: Harbinger of classic stage 4 neuroblastoma in an infant cured despite residual disease after minimal therapy.
    Pediatr Blood Cancer, 53(7): 1340-2. [Abstract] [Full-text]
57. Low-dose oral midazolam reduces fear and distress during needle procedures in children with cancer.
    Pediatr Blood Cancer, 53(7): 1200-4. [Abstract] [Full-text]
58. Citrulline as a marker for chemotherapy induced mucosal barrier injury in pediatric patients.
    Pediatr Blood Cancer, 53(7): 1188-94. [Abstract] [Full-text]
59. Veno-occlusive disease as a complication of preoperative chemotherapy for Wilms tumor: A clinico-pathological analysis.
    Pediatr Blood Cancer, 53(7): 1211-5. [Abstract] [Full-text]
60. The CB1 antagonist rimonabant (SR141716) blocks cue-induced reinstatement of cocaine seeking and other context and extinction phenomena predictive of relapse.
    Drug Alcohol Depend, 105(3): 248-55. [Abstract] [Full-text]
61. Efficacy and safety of microfoam sclerotherapy in a patient with Klippel-Trenaunay syndrome and a patent foramen ovale.
    Arch Dermatol, 145(10): 1147-51. [Abstract] [Full-text]
62. Acyclic retinoid synergises with valproic acid to inhibit growth in human hepatocellular carcinoma cells.
    Cancer Lett, 285(2): 210-7. [Abstract] [Full-text]
63. Drug development perspective on pharmacokinetic studies of new drugs in patients with renal impairment.
    Clin Pharmacol Ther, 86(5): 557-61. [Abstract] [Full-text]
64. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma.
    N Engl J Med, 361(17): 1662-70. [Abstract] [Full-text]
65. From means to ends: artificial nutrition and hydration.
    Nurs Clin North Am, 44(4): 505-15. [Abstract] [Full-text]
66. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.
    Blood, 114(17): 3533-7. [Abstract] [Full-text]
67. Chitosan-alginate microcapsules for oral delivery of egg yolk immunoglobulin (IgY): effects of chitosan concentration.
    Appl Biochem Biotechnol, 159(3): 778-87. [Abstract] [Full-text]
68. Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women.
    Am J Med, 122(11): 1016-1022.e1. [Abstract] [Full-text]
69. Use of a battery-operated needle driver for intraosseous access by novice users: skill acquisition with cadavers.
    Ann Emerg Med, 54(5): 692-4. [Abstract] [Full-text]
70. GLUT-1 expression and response to chemoradiotherapy in rectal cancer.
    Int J Cancer, 125(12): 2778-82. [Abstract] [Full-text]
71. The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38.
    Int J Cancer, 125(12): 2957-69. [Abstract] [Full-text]
72. Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy.
    J Infect Dis, 200(10): 1490-7. [Abstract] [Full-text]
73. Combined adjuvant radiochemotherapy with IMRT/XELOX improves outcome with low renal toxicity in gastric cancer.
    Int J Radiat Oncol Biol Phys, 75(4): 1187-95. [Abstract] [Full-text]
74. In vitro performance of an injectable hydrogel/microsphere based immunocyte delivery system for localised anti-tumour activity.
    Biomaterials, 30(36): 6986-95. [Abstract] [Full-text]
75. Perlecan domain I-conjugated, hyaluronic acid-based hydrogel particles for enhanced chondrogenic differentiation via BMP-2 release.
    Biomaterials, 30(36): 6964-75. [Abstract] [Full-text]
76. Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer.
    Biomaterials, 30(36): 6976-85. [Abstract] [Full-text]
77. Chemotherapy-induced neutropenia as a prognostic factor in advanced non-small-cell lung cancer: results from Japan Multinational Trial Organization LC00-03.
    Br J Cancer, 101(9): 1537-42. [Abstract] [Full-text]
78. Vascular-targeted photodynamic therapy with BF2-chelated Tetraaryl-Azadipyrromethene agents: a multi-modality molecular imaging approach to therapeutic assessment.
    Br J Cancer, 101(9): 1565-73. [Abstract] [Full-text]
79. A phase-II trial of dose-dense chemotherapy in patients with disseminated thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9605).
    Br J Cancer, 101(9): 1549-54. [Abstract] [Full-text]
80. The association between food insecurity and mortality among HIV-infected individuals on HAART.
    J Acquir Immune Defic Syndr, 52(3): 342-9. [Abstract] [Full-text]
81. Microinjection in a microfluidic format using flexible and compliant channels and electroosmotic dosage control.
    Lab Chip, 9(22): 3202-11. [Abstract] [Full-text]
82. Long-term prognostic value of ST-segment resolution in patients treated with fibrinolysis or primary percutaneous coronary intervention results from the DANAMI-2 (DANish trial in acute myocardial infarction-2).
    J Am Coll Cardiol, 54(19): 1763-9. [Abstract] [Full-text]
83. Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group.
    J Clin Oncol, 27(31): 5189-94. [Abstract] [Full-text]
84. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study.
    J Clin Oncol, 27(31): 5175-81. [Abstract] [Full-text]
85. Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer.
    J Clin Oncol, 27(31): 5248-54. [Abstract] [Full-text]
86. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.
    J Clin Oncol, 27(31): 5182-8. [Abstract] [Full-text]
87. Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks?
    J Clin Oncol, 27(31): 5138-43. [Abstract] [Full-text]
88. 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen.
    J Clin Oncol, 27(31): 5208-12. [Abstract] [Full-text]
89. Enlightened protein: Fhit tumor suppressor protein structure and function and its role in the toxicity of protoporphyrin IX-mediated photodynamic reaction.
    Toxicol Appl Pharmacol, 241(2): 246-52. [Abstract] [Full-text]
90. Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors.
    Blood, 114(18): 3956-9. [Abstract] [Full-text]
91. Enhanced photodynamic efficacy towards melanoma cells by encapsulation of Pc4 in silica nanoparticles.
    Toxicol Appl Pharmacol, 241(2): 163-72. [Abstract] [Full-text]
92. Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol.
    Blood, 114(18): 3764-8. [Abstract] [Full-text]
93. Cytotoxicity of solubilization vehicles for Trichomonas gallinae and Tritrichomonas foetus measured by the resazurin microtiter assay.
    Vet Parasitol, 166(1): 167-70. [Abstract] [Full-text]

© 2004-2012 Chemotherapy Research Today. All Rights Reserved.